ES2134459T3 - Indeno(1,2-e)pirazina-4-onas, su preparacion y los medicamentos que les contienen. - Google Patents

Indeno(1,2-e)pirazina-4-onas, su preparacion y los medicamentos que les contienen.

Info

Publication number
ES2134459T3
ES2134459T3 ES95914403T ES95914403T ES2134459T3 ES 2134459 T3 ES2134459 T3 ES 2134459T3 ES 95914403 T ES95914403 T ES 95914403T ES 95914403 T ES95914403 T ES 95914403T ES 2134459 T3 ES2134459 T3 ES 2134459T3
Authority
ES
Spain
Prior art keywords
pct
receptor
pirazina
onas
indeno
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95914403T
Other languages
English (en)
Inventor
Jean-Claude Aloup
Francois Audiau
Michel Barreau
Dominique Damour
Arielle Genevois-Borella
Patrick Jimonet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Rhone Poulenc Rorer SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer SA filed Critical Rhone Poulenc Rorer SA
Application granted granted Critical
Publication of ES2134459T3 publication Critical patent/ES2134459T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)

Abstract

COMPUESTOS DE LA FORMULA (I) CONDE R ES UN ATOMO DE NITROGENO, OXIGENO O AZUFRE SUSTITUIDO O UN RADICAL C=R{SUB,3}, C(R{SUB,4}R{SUB,5} O CH-R{SUB,6}; R{SUB,1} ES UN RADICAL HIDROXI, POLIFLUOROALCOXI, CARBOXI, ALCOXICARBONIL, -NH-CHO O -NH-CON(ALQ)AR DONDE AR ES OPCIONALMENTE SUSTITUIDO, -N(ALQ)-CONR{SUB,8}R{SUB,9}, -N(ALQ-AR)-CO-NR{SUB,8}R{SUB,9}, -NH-CONR{SUB,9}R{SUB,12}, -NH-CS-NR{SUB,8}R{SUB,9}, N-(ALQ)-CSNR{SUB,8}R{SUB,9}, -NH-CO-R{SUB,10}, -NH-CS-R{SUB,20}, -NHC(=NR{SUB,21}-NR{SUB,7}R{SUB,9}, SO{SUB,2}-NR{SUB,7}R{SUB,9}, OPCIONALMENTE 3-SUSTITUIDO 2-OXO-1-IMIDAZOLIDINIL U OPCIONALMENTE 3-SUSTITUIDO 2-OXO-1 PERHIDROPIRIMIDINIL; R{SUB,2} ES UN ATOMO DE HIDROGENO O HALOGENO O UN RADICAL ALQUILO, ALCOXI, AMINO, NHCO-NH-AR, N=CH.N(ALQ)ALQ'', NITRO, CIANO, FENIL, IMIDAZOLIL, ACILAMINO, SO{SUB,3}H, HIDROXI, POLIFLUOROALCOXI, CARBOXI, ALCOXICARBONIL, -NH-CHO, -NH-CO-N(ALQ)AR EN DONDE AR ES OPCIONALMENTE SUSTITUIDO, -N(ALQ)-CO-NR{SUB,8}R{SUB,9}, -NHSO{SUB,2}-NR{SUB,7}R{SUB,9}, -N(ALQ-AR)-CO-NR{SUB,8}R{SUB,9}, NH-CO-NR{SUB,9}R{SUB,12}, -NH-CS-NR{SUB,8}R{SUB,9}, -N(ALQ)-CSNR{SUB,8}R{SUB,9}, -NH-CO-R{SUB,10}, -NH-CS-R{SUB,20}, -NHC(NR{SUB,21})NR{SUB,7}R{SUB,9}, -NH-SO{SUB,2}-NR{SUB,7}R{SUB,9}, N-(ALQ)-SO{SUB,2}-NR{SUB,7}R{SUB,9}, -CO-NR{SUB,7}R{SUB,9}, -NHSO{SUB,2}ALQ, -NR{SUB,9}R{SUB,11}, -S(O){SUB,M}-ALQ-AR, SO{SUB,2}-NR{SUB,7}R{SUB,9}, OPCIONALMENTE 3-SUSTITUIDO 2-OXO-1IMIDAZOLIDINIL U OPCIONALMENTE 3-SUSTITUIDO 2-OXO-1PERHIDROPIRIMIDINIL; R{SUB,3} ES UN ATOMO DE OXIGENO O UN RADICAL NOH, NO-ALQ-COOX O CH-R{SUB,13}, R{SUB,4} ES UN RADICAL ALQUIL, -ALQ-HET O ALQ-AR; R{SUB,5} ES UN RADICAL ALQUILO C{SUB,1-11} RECTO O RAMIFICADO, ALQ-HET O ALQ-AR, O R{SUB,4} Y R{SUB,5} TOMADOS JUNTO CON EL ATOMO DE CARBONO AL QUE ESTAN UNIDOS FORMAN UN RADICAL CICLOALQUILO; R{SUB,6} ES UN RADICAL DE UN ATOMO DE HIDROGENO O UN RADICAL HIDROXI, O ALQUIL RECTO O RAMIFICADO C{SUB,1}-{SUB,11}, -NR{SUB,14}R{SUB,15}, -ALQ-HO, ALQNR{SUB,14}R{SUB,15}, ALQ-AR O -ALQ-HET; O SALES DE LOS MISMOS. LOS COMPUESTOS DE LA FORMULA (I) SON ANTAGONISTAS DEL RECEPTOR N-METIL-ASPARTATO- (NMDA) NO COMPETITIVOS, EN CONCRETO LIGANDOS DEL LUGAR DE MODULACION DE LA GLICINA RECEPTORA NMDA, Y SON ANTAGONISTAS DEL RECEPTOR DEL ACIDO ALFA-AMINO-3-HIDROXI-5-METIL4-ISOXAZOLAPROPIONICO, SIENDO TAMBIEN CONOCIDO DICHO RECEPTOR COMO RECEPTOR QUISCUALATO.
ES95914403T 1994-03-28 1995-03-23 Indeno(1,2-e)pirazina-4-onas, su preparacion y los medicamentos que les contienen. Expired - Lifetime ES2134459T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9403581A FR2717812B1 (fr) 1994-03-28 1994-03-28 Indeno[1,2-e]pyrazine-4-ones, leur préparation et les médicaments les contenant.

Publications (1)

Publication Number Publication Date
ES2134459T3 true ES2134459T3 (es) 1999-10-01

Family

ID=9461466

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95914403T Expired - Lifetime ES2134459T3 (es) 1994-03-28 1995-03-23 Indeno(1,2-e)pirazina-4-onas, su preparacion y los medicamentos que les contienen.

Country Status (13)

Country Link
US (1) US5789406A (es)
EP (1) EP0752991B1 (es)
JP (1) JPH09510726A (es)
AT (1) ATE180483T1 (es)
AU (1) AU2141295A (es)
DE (1) DE69509888T2 (es)
DK (1) DK0752991T3 (es)
ES (1) ES2134459T3 (es)
FR (1) FR2717812B1 (es)
GR (1) GR3030273T3 (es)
IL (1) IL113147A0 (es)
WO (1) WO1995026349A1 (es)
ZA (1) ZA952531B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2743366B1 (fr) * 1996-01-10 1998-02-06 Rhone Poulenc Rorer Sa Derives de 5h,10h-imidazo(1,2-a)indeno(1,2-e)pyrazine-4-one, leur preparation, leurs intermediaires et les medicaments les contenant
NZ528639A (en) * 2001-03-14 2005-07-29 Gruenenthal Chemie Substituted pyrazolopyrimidines and thiazolopyrimidines used as analgesics
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
US7320992B2 (en) * 2003-08-25 2008-01-22 Amgen Inc. Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use
US8278345B2 (en) 2006-11-09 2012-10-02 Probiodrug Ag Inhibitors of glutaminyl cyclase
US9126987B2 (en) 2006-11-30 2015-09-08 Probiodrug Ag Inhibitors of glutaminyl cyclase
JP5930573B2 (ja) 2007-03-01 2016-06-15 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤の新規使用
JP5667440B2 (ja) 2007-04-18 2015-02-12 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのチオ尿素誘導体
PL2475428T3 (pl) 2009-09-11 2015-12-31 Probiodrug Ag Pochodne heterocykliczne jako inhibitory cyklazy glutaminowej
EP2542549B1 (en) 2010-03-03 2016-05-11 Probiodrug AG Inhibitors of glutaminyl cyclase
US8269019B2 (en) 2010-03-10 2012-09-18 Probiodrug Ag Inhibitors
US8541596B2 (en) 2010-04-21 2013-09-24 Probiodrug Ag Inhibitors
US8530670B2 (en) 2011-03-16 2013-09-10 Probiodrug Ag Inhibitors
ES2812698T3 (es) 2017-09-29 2021-03-18 Probiodrug Ag Inhibidores de glutaminil ciclasa

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4668678A (en) * 1980-05-09 1987-05-26 Usv Pharmaceutical Corporation Triazoloquinoxalin-1,4-diones
US4507300A (en) * 1980-05-09 1985-03-26 Usv Pharmaceutical Corporation Pyridotriazolopyrazine-diones for treating allergy
US4400382A (en) * 1980-05-09 1983-08-23 Usv Pharmaceutical Corporation Thiazoloquinoxalin-1,4-diones for treating allergy
US4354027A (en) * 1980-05-19 1982-10-12 Usv Pharmaceutical Corporation Triazoloquinoxalin-4-ones
US5191197A (en) * 1988-05-11 1993-03-02 Symbol Technologies, Inc. Arm mounted scanner actuatable by hand movement
US5196421A (en) * 1991-06-05 1993-03-23 Eli Lilly And Company Excitatory amino acid receptor antagonists in methods for the use thereof
US5153196A (en) * 1991-06-05 1992-10-06 Eli Lilly And Company Excitatory amino acid receptor antagonists and methods for the use thereof
DK162491D0 (da) * 1991-09-20 1991-09-20 Novo Nordisk As Heterocycliske forbindelser, deres fremstilling og farmaceutiske praeparater indeholdende forbindelserne
EP0647137B1 (en) * 1992-06-22 2008-08-13 The Regents Of The University Of California Glycine receptor antagonists and the use thereof
FR2696466B1 (fr) * 1992-10-02 1994-11-25 Rhone Poulenc Rorer Sa Dérivés de 5H,10H-imidazo[1,2-a]indeno[1,2-e]pyrazine-4-one, leur préparation et les médicaments les contenant.
DK12293D0 (da) * 1993-02-02 1993-02-02 Novo Nordisk As Heterocykliske forbindelser og deres fremstilling og anvendelse
FR2707643B1 (fr) * 1993-07-16 1995-08-11 Rhone Poulenc Rorer Sa Dérivés d'imidazo[1,2-a]pyrazine-4-one, leur préparation et les médicaments les contenant.
FR2707645B1 (fr) * 1993-07-16 1995-08-11 Rhone Poulenc Rorer Sa Dérivés d'imidazo[1,2-a]pirazine-4-one, leur préparation et les médicaments les contenant.

Also Published As

Publication number Publication date
ZA952531B (en) 1996-01-11
DE69509888T2 (de) 1999-09-30
AU2141295A (en) 1995-10-17
JPH09510726A (ja) 1997-10-28
EP0752991A1 (fr) 1997-01-15
FR2717812B1 (fr) 1996-05-10
IL113147A0 (en) 1995-06-29
US5789406A (en) 1998-08-04
GR3030273T3 (en) 1999-08-31
DK0752991T3 (da) 1999-11-08
DE69509888D1 (de) 1999-07-01
ATE180483T1 (de) 1999-06-15
WO1995026349A1 (fr) 1995-10-05
FR2717812A1 (fr) 1995-09-29
EP0752991B1 (fr) 1999-05-26

Similar Documents

Publication Publication Date Title
ATE175114T1 (de) Pharmazeutische zusammensetzungen enthaltend einen opiat antagonist und calcium salze, ihre verwendung zur behandlung von endorphin- vermittelten krankheiten
ES2134459T3 (es) Indeno(1,2-e)pirazina-4-onas, su preparacion y los medicamentos que les contienen.
ATE171445T1 (de) Perhydroisoindolderivate als substanz p antagonisten
ATE180476T1 (de) 5h-indeno(1,2-b>pyrazin-2,3-dion-derivate antagonisten der ampa und nmda rezeptoren
ES2158099T3 (es) Derivados de imidazo(1,2-a)indeno(1,2-e)pirazina-4-ona y composiciones farmaceuticas que los contienen.
DK0756602T3 (da) CCK- eller gastrin-modulerende 5-heterocyclo-1,5-benzodiazepiner
NO301760B1 (no) Farmakologisk aktive <alfa>-[tertiær-aminometyl]-benzenmetanolderivater, farmasöytiske preparater inneholdende disse samt anvendelse av forbindelsene for fremstilling av farmasöytiske preparater
FI971528A0 (fi) Pyrrolyylitetrahydrobentsokinoksaliinidionit, niiden valmistus ja käyttö glutamaattireseptoriantagonisteina
DK0766695T3 (da) Pyrrolidinderivater til behandling af CCK- og gastrinrelaterede sygdomme
ES2099973T3 (es) Derivados de ureido-acetamida su preparacion y los medicamentos que los contienen.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 752991

Country of ref document: ES